SCHEMBL2653262

SCHEMBL2653262

CCOC(=O)c1ccc(Nc2cccc(CO)c2)c(N)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 6/20 0.58
PTGER4 P35408 3/20 0.55
ALOX15 P16050 1/20 0.51
GAA P10253 4/20 0.50
NPC1 O15118 4/20 0.50
GFER P55789 2/20 0.50
KDM4E B2RXH2 3/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 3/20 0.47
ALDH1A1 P00352 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CDC25A P30304 1/20 0.47
CDC25C P30307 1/20 0.47
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
TP53 P04637 1/20 0.46
PRMT1 Q99873 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2668062 0.86 GAA (0.45) CDC25BPTGER4ALOX15GAANPC1
SCHEMBL15319909 0.85 GAA (0.65) CDC25BPTGER4ALOX15GAANPC1
SCHEMBL13220613 0.84 CDC25B (0.50) CDC25BNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL2653630 0.82 KMT2A (0.60) CDC25BPTGER4NPC1KDM4ERAB9A
SCHEMBL12135316 0.80 CDC25B (0.66) CDC25BPTGER4GAANPC1GFER
SCHEMBL12136818 0.79 CDC25B (0.80) CDC25BNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL14306866 0.79 PTGER4 (0.60) CDC25BPTGER4ALOX15GAANPC1
SCHEMBL12135311 0.79 CDC25B (0.65) CDC25BPTGER4GAANPC1GFER
SCHEMBL1356848 0.78 CDC25B (0.64) CDC25BPTGER4GAANPC1GFER
SCHEMBL1357593 0.77 CDC25B (0.62) CDC25BPTGER4GAANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 CDC25B 4130/4885PTGER4 1460/4885ALOX15 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.